Compare Cassava Sciences Inc (FLNA) vs Northrop Grumman Corporation (NOC) Price & Performance

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Northrop Grumman (NOC) trades at $571.58, up 0.68% on the day, with a bullish technical signal driven by moving averages despite overbought RSI readings. The company reported strong Q2 2026 earnings, beating EPS estimates with $7.68 actual versus $6.82 expected, and raised full-year guidance amid a record $105 billion backlog. Fundamentals show robust profitability with a 10.48% net income margin and 26.96% ROE, while valuation metrics like a P/E of 18.17 appear reasonable relative to growth.

Outlook remains positive given defense spending tailwinds and contract wins like the $7.6 billion Sentinel program, though margin pressures and high debt levels pose risks. Analysts are bullish with a $598.57 consensus target, implying ~5% upside from current levels, supported by 20 buy ratings versus 1 sell.